NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-198-2025-0-US-09 VIRAL SEROLOGY ASSAYS US 63/074,073 Expired
NHLBI E-218-2016-1-US-03 Immunogens, Compositions, And Methods For Treating Dyslipidemia US National Stage 16/977,648 11633471 Issued PDF
NCI E-163-2020-0-US-01 LZK-TARGETING DEGRADERS AND METHODS OF USE US 63/073,835 Abandoned
NCI E-097-2018-0-AU-04 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES AU National Stage 2019235926 Pending
NCATS E-117-2018-0-US-03 2,6-DIMETHOXY-4-(5-PHENYL-4-THIOPHENE-2-YL-1H-IMIDAZOL-2-YL)-PHENOL (DPTIP) A SMALL MOLECULE INHIBITOR OF NEUTRAL SPHINGOMYELINASE 2 (nSMase-2) FOR THE TREATMENT OF
NEURODEGENERATIVE AND ONCOLOGIC DISEASES 		US National Stage 16/977,305 11766423 Issued PDF
NIAID E-089-2002-1-US-89 Dengue Tetravalent Vaccine Containing A Common 30 Nucleotide Deletion In The 3'-UTR Of Dengue Types 1,2,3, And 4, Or Antigenic Chimeric Dengue Viruses 1,2,3, And 4 US DIV 17/009,448 11753627 Expired PDF
NCI E-097-2018-0-IL-09 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IL National Stage 277078 Pending
NIAID E-297-2016-2-US-07 VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES US CON 17/008,025 11390651 Issued PDF
NHLBI E-126-2020-0-US-01 Methods To Produce Very Long Chain Fatty Acids (VLCFA) US 63/072,519 Abandoned
NCATS E-084-2020-0-PCT-02 Preparation Of Benzene-1,4-disulfonamide Derivatives Useful As Therapeutic TRPML1 Receptor Modulators PCT PCT PCT/US2020/048482 Expired
NCATS E-084-2020-0-US-03 SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF US National Stage 17/638,929 Abandoned
NIAID E-048-2020-0-PCT-02 COMPOSITIONS INCLUDING IGG Fe MUTATIONS AND USES THEREOF PCT PCT PCT/US2020/048253 Expired
NCATS E-014-2022-0-US-01 HYDROXYNORKETAMINE COMPOUNDS AND METHODS OF USE THEREOF US 63/071,334 Abandoned
NIAID E-145-2021-1-US-01 Adjuvanted Stabilized Stem Hemagglutinin Nanoparticles And Methods Of Using The Same To Induce Broadly Neutralizing Antibodies Against Influenza US 63/071,244 Abandoned
NCATS E-253-2017-0-US-03 C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME US National Stage 16/976,012 11649218 Issued PDF
NCI E-171-2018-9-US-06 MODIFIED CELLS AND METHODS OF THERAPY US CON 17/003,081 11583556 Issued PDF
NCI E-029-2022-1-US-01 Q-Griffithsin Nasal Spray US 63/070,375 Abandoned
NCI E-182-2019-1-US-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER US 63/070,739 Abandoned
NCI E-192-2020-1-US-01 USE OF AGONISTS TO AUGMENT CART FUNCTION IN SOLID TUMORS US 63/069,649 Abandoned
NCI E-266-2011-0-EP-37 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage EP DIV 20192082.4 Issued
NCI E-266-2011-0-GB-01 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage GB EP 20192082.4 Issued
NCI E-266-2011-0-DE-01 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage DE EP 20192082.4 Issued
NCI E-266-2011-0-FR-01 T Cell Receptors Recognizing HLA-A1-or HLA-CW7- Restricted Mage FR EP 20192082.4 Issued
NIAID E-034-2018-0-US-08 NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE US National Stage 16/971,826 11760790 Issued PDF
NCI E-109-2020-0-US-01 HIGH-THROUGHPUT GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES US 63/068,458 Abandoned
NCI E-059-2013-0-AU-13 Methods of Producing Enriched Populations of Tumor-Reactive T Cells From Tumor AU DIV 2020220209 Abandoned
NCI E-248-2020-0-PCT-02 PROTEIN PANELS FOR THE EARLY DIAGNOSIS/PROGNOSIS AND TREATMENT OF AGGRESSIVE PROSTATE CANCER PCT PCT PCT/US2020/047069 Expired
NEI E-091-2018-0-US-06 USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION US National Stage 16/971,288 Pending
NCI E-248-2020-0-EP-04 Protein Panels For The Early Diagnosis/Prognosis Of Aggressive Prostate Cancer EP National Stage 20855632.4 Pending
NIAID E-085-2018-0-US-04 CD153 AND/OR CD30 IN INFECTION US National Stage 16/971,144 Abandoned
NCI E-248-2020-0-CA-03 Protein Panels For The Early Diagnosis/Prognosis Of Aggressive Prostate Cancer CA National Stage 3147509 Pending
NCI E-068-2018-0-ES-01 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 ES EP 19709154.9 Issued
NCI E-068-2018-0-EP-05 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 EP National Stage 19709154.9 Issued
NCI E-068-2018-0-GB-01 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 GB EP 19709154.9 Issued
NCI E-036-2018-0-US-02 HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMS US National Stage 16/970,155 11787764 Issued PDF
NEI E-195-2020-0-US-01 Sensitive And Economic RNA Virus Detection Using A Novel RNA Preparation Method US 63/065,931 Abandoned
NIBIB E-054-2018-0-US-06 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING US National Stage 16/969,673 12161733 Issued PDF
NIA E-139-2012-2-US-15 METHODS OF REGULATING CANNABINOID RECEPTOR ACTIVITY-RELATED DISORDERS AND DISEASES US CON 16/992,742 11389415 Issued PDF
NCI E-046-2019-0-US-06 Non-aggregating Heptamethine Cyanine Fluorophores For In Vivo Imaging US National Stage 16/969,902 10961193 Issued PDF
NCI E-107-2020-0-US-01 IGG4 HINGE-CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GLYPICAN-1 (GPC1) FOR TREATING SOLID TUMORS US 63/065,388 Abandoned
NIBIB E-054-2018-0-IL-05 CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER IL National Stage 276653 Issued
NIAID E-035-2018-0-US-03 TREATMENT OF INFECTIONS AND IMMUNE DYSREGULATION IN PATIENTS WITH PRIMARY IMMUNE DEFICIENCIES USING MRNA-CORRECTED AUTOLOGOUS GRANULOCYTES, LYMPHOCYTES AND/OR NATURAL KILLER CELLS US National Stage 16/968,792 Abandoned
NIDDK E-028-2018-1-CN-04 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS CN National Stage 201980012696.0 Abandoned
NIAID E-105-2020-0-US-01 Replication-Competent Adenovirus Type 4-HIV Env Vaccines And Their Use US 63/063,810 Abandoned
NCATS E-200-2020-0-US-01 REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY US 63/063,689 Abandoned
NCI E-068-2018-0-AU-03 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 AU National Stage 2019218785 Issued
NIDA E-023-2018-0-US-04 DREADD ACTUATORS US National Stage 16/968,437 11739063 Issued PDF
NCI E-068-2018-0-CN-04 TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 CN National Stage 201980012443.3 Pending
NIDDK E-028-2018-1-CA-03 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS CA National Stage 3090788 Abandoned
NCI E-126-2019-0-PCT-02 T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY PCT PCT PCT/US2020/045100 Expired